PB Fintech Share Price In Focus As Jefferies, Morgan Stanley And BofA Rework Stock Targets After IRDAI Proposal

PB Fintech share price remained volatile on Friday, September 25, after the stock lost 36% in the previous session and extended its decline to around 40% over two trading sessions. The Policybazaar parent had closed at ₹1,207.20 on Thursday, down ₹679.10 in a single day, after hitting a fresh 52-week low. The stock opened at ₹1,131.05 on Friday and later touched an intraday high of ₹1,262.

The sharp fall has brought the PB Fintech share price into focus after the stock dropped from ₹1,886.30 on September 23 to ₹1,207.20 on September 24. The sell-off erased more than ₹31,000 crore from the company's market value in a single session, with the stock's market capitalisation falling to around ₹55,860 crore.

The market reaction has also triggered a reassessment of PB Fintech's valuation by global brokerages. Jefferies has cut its target price to ₹1,540 from ₹2,050 while retaining its Buy rating, BofA Securities has lowered its target to ₹1,410 from ₹1,970 while maintaining its Neutral rating, and Morgan Stanley has flagged a potentially sharp impact on the company's health insurance business under the proposed IRDAI framework.

PB Fintech share price: Jefferies cuts target to ₹1,540

Jefferies has reduced its target price on PB Fintech by about 25% to ₹1,540 from ₹2,050, while retaining its Buy rating. The brokerage expects the proposed changes to have a larger impact on the company’s non-life insurance business than on life insurance.

According to the firm, a 10% reduction in new-business commission rates could result in a 10-12% decline in earnings. The brokerage has also pointed to cost optimisation as an immediate area of focus for PB Fintech if the proposed regulations are implemented.

Jefferies has not yet changed its earnings estimates but has lowered the valuation multiple assigned to the company because of uncertainty over future take rates. It has also noted that PB Fintech could slow hiring and reduce marketing expenditure as it adjusts to the changing insurance distribution environment.

The brokerage has also highlighted that the IRDAI proposals are still under consultation. The final regulations could therefore differ from the provisions contained in the current paper.

PB Fintech share price: BofA cuts target to ₹1,410

BofA Securities has retained its Neutral rating on PB Fintech but reduced its target price to ₹1,410 from ₹1,970, a cut of around 28%. The brokerage expects the proposed distribution changes to put pressure on the economics of online insurance broking.

BofA expects the impact on Policybazaar’s life and term insurance business to remain manageable. It has also identified the possibility of the platform gaining market share across insurance categories as one factor that could support the business.

The brokerage has lowered the valuation multiple for PB Fintech’s core business following the regulatory proposal. It has also pointed to potential opportunities around insurance manufacturing and PB Health’s hospital business, although these remain areas the company would need to develop further.

PB Fintech share price: Morgan Stanley flags health business impact

Morgan Stanley has focused on the potential effect of the proposed commission structure on PB Fintech’s health insurance business.

The brokerage estimates that the health business’s NPV could decline by 60-70% under the proposed framework, while the impact on life insurance NPV could be comparatively limited. Morgan Stanley has also flagged a potential risk to the revenue of PB Partners’ point-of-sale person (POSP) business.

At the same time, Morgan Stanley said PB Fintech is evaluating additional opportunities, including insurance manufacturing, reinsurance broking and new products. The company is also seeking a managing general agent framework, which could create another avenue within the insurance distribution market.

The brokerage has also noted PB Fintech’s plans to reduce losses at Paisabazaar and its UAE operations as part of efforts to improve the performance of its other businesses.

IRDAI proposal remains key trigger

The brokerage revisions follow IRDAI’s consultation paper proposing changes to insurance distribution economics. The proposed framework includes tighter commission structures across insurance categories, changes to expense-of-management rules and restrictions on certain practices used on insurance websites.

For PB Fintech, the key issue is the potential effect on commissions generated from insurance distribution. A reduction in the amount insurers can spend on commissions and distribution could affect the economics of Policybazaar’s business and alter revenue and earnings assumptions.

However, the proposals are not final. IRDAI has invited stakeholder feedback, and the provisions could change before the regulator issues the final rules.

The regulatory proposal has therefore become the main variable behind the latest reassessment of PB Fintech’s share price. Jefferies, BofA Securities and Morgan Stanley have each identified different areas of potential impact, ranging from commission rates and non-life insurance to the valuation of the company’s health business.

Also Read - UPI MDR From October 15: Finance Minister Nirmala Sitharaman Clarifies Who Pays 0.4% Charge On Payments Above ₹2,000